CompletedInterventional · Phase 2NCT01622868 ↗Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer - A Collaborative Study of NRG Oncology and KROG
CompletedInterventional · Phase 2NCT01936831 ↗The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive TuberculosisJean W. PapePIInterventionDrug: Isoniazid · Dietary supplement: Vitamin B6DatesAug 2014 – Sep 2021· Results postedSponsorNational Institute of Allergy & Infectious DiseasesTuberculosis
CompletedInterventional · Phase 2NCT02266745 ↗A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsScott T. TagawaPIInterventionDrug: PT-112 InjectionDatesJul 2014 – Aug 2024 (est.)SponsorPhosplatin TherapeuticsAdvanced Solid TumorsCRPCmCRPC+6 more
CompletedInterventional · Phase 2NCT02365649 ↗A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Upadacitinib (ABT-494) for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF TherapyAliza B SolomonPIInterventionDrug: Placebo · Drug: ABT-494DatesMar 2015 – Nov 2016· Results postedSponsorAbbVie Inc.Crohn's Disease
CompletedInterventional · Phase 2NCT02807272 ↗A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other Myelodysplastic /Myeloproliferative Neoplasias, and Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: TipifarnibDatesJan 2017 – Nov 2020· Results postedSponsorKura OncologyLeukemia, Myelomonocytic, Chronic
CompletedInterventional · Phase 2NCT02859558 ↗Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune ResponsesTimothy WilkinPIInterventionDrug: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapyDatesJan 2017 – Dec 2020· Results postedSponsorAIDS Clinical Trial GroupHIV-1 Infection
CompletedInterventional · Phase 2NCT02952534 ↗TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination DeficiencyCora SternbergPIInterventionDrug: RucaparibDatesFeb 2017 – Jul 2021· Results postedSponsorClovis Oncology, Inc.Metastatic Castration Resistant Prostate Cancer
CompletedInterventional · Phase 2NCT03011372 ↗A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)Ellen K. RitchiePIInterventionDrug: PemigatinibDatesApr 2017 – Oct 2024· Results postedSponsorIncyte, Inc.MPN (Myeloproliferative Neoplasms)
CompletedInterventional · Phase 2NCT03222609 ↗A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)Ellen K. RitchiePIInterventionDrug: Ruxolitinib · Drug: NavitoclaxDatesOct 2017 – Mar 2022· Results postedSponsorAbbVie Inc.Myelofibrosis (MF)
CompletedInterventional · Phase 2NCT03413995 ↗Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)Cora SternbergPIInterventionDrug: RucaparibDatesSep 2018 – Nov 2023· Results postedSponsorThe Johns Hopkins UniversityProstate Cancer Metastatic
CompletedInterventional · Phase 2NCT03532035 ↗A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus ViremiaAlexander DrelickPIInterventionDrug: Brincidofovir · Drug: Standard of CareDatesDec 2018 – May 2019SponsorChimerix, Inc.Adenovirus
CompletedInterventional · Phase 2NCT03538041 ↗A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic AnemiaMaria Teresa DeSanchoPIInterventionDrug: ParsaclisibDatesNov 2018 – Aug 2021· Results postedSponsorIncyte, Inc.Autoimmune Hemolytic Anemia
CompletedInterventional · Phase 2NCT03539302 ↗A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial FibrillationJames E. IpPIInterventionDrug: Flecainide AcetateDatesMay 2018 – Jan 2022· Results postedSponsorInCarda TherapeuticsParoxysmal Atrial Fibrillation (PAF)
CompletedInterventional · Phase 2NCT03541603 ↗A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)Evelyn M. HornPIInterventionDrug: Levosimendan · Drug: Matching PlaceboDatesNov 2018 – Apr 2020· Results postedSponsorTenax Therapeutics Inc.Hypertension Pulmonary SecondaryHeart Failure, Right SidedHeart Failure With Normal Ejection Fraction
CompletedInterventional · Phase 2NCT03557359 ↗A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating AgentsHoward Alan FinePIInterventionDrug: NivolumabDatesJun 2018 – Sep 2022· Results postedSponsorColumbia UniversityGliomas
CompletedInterventional · Phase 2NCT03558152 ↗A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative ColitisRandy LongmanPIInterventionDrug: UTTR1147A · Drug: UTTR1147A Placebo · Drug: Vedolizumab · Drug: Vedolizumab PlaceboDatesOct 2018 – Dec 2021· Results postedSponsorGenentech, Inc.Ulcerative Colitis
CompletedInterventional · Phase 2NCT03558503 ↗A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of RecurrenceDouglas S ScherrPIInterventionDrug: UGN-102DatesOct 2018 – Jan 2020· Results postedSponsorUroGen Pharma Ltd.Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
CompletedInterventional · Phase 2NCT03583164 ↗Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment OptionsMarkus PlatePIInterventionDrug: OlorofimDatesJun 2018 – Feb 2023· Results postedSponsorF2G LtdInvasive Fungal Infections
CompletedInterventional · Phase 2NCT03603808 ↗A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive IndividualsGrant EllsworthPIInterventionDevice: Electroporation · Biological: HPV DNA Plasmids Therapeutic Vaccine VGX-3100 · Other: Laboratory Biomarker AnalysisDatesSep 2018 – Dec 2024· Results postedSponsorAIDS Malignancy ConsortiumAnal Intraepithelial NeoplasiaHigh Grade Squamous Intraepithelial NeoplasiaHIV Positivity+2 more
CompletedInterventional · Phase 2NCT03637556 ↗A Multi-Center, Open-Label, Two-Period Cross-Over, Patient-Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Iron Chelating Activity of DST-0509 (Deferasirox) Tablets in Thalassemia Patients With Inadequate Response to Standard Chelation TherapySujit ShethPIInterventionDrug: DST-0509 · Drug: Jadenu · Drug: ExjadeDatesAug 2019 – Jun 2021SponsorDisperSol TechnologiesThalassemia Major